Channel Medsystems, Inc.

Channel Medsystems, Inc. specializes in cryosurgical systems, which are designed to freeze and destroy tissue in controlled medical procedures. Their primary product category includes general cryosurgical systems, electronic devices, and associated cryogen gases. An example of their offerings is the Cerene Cryotherapy Device, which is used for cryoablation—freezing tissue to treat conditions like tumors or skin lesions. Accessories like exhaust collection bags are also part of their portfolio to support these procedures.

Channel Medsystems, Inc. is based in the United States. Their devices are listed in multiple regulatory registries, including the EU’s eudamed database for medical device transparency, as well as the U.S. FDA’s Premarket Approval (PMA) and Unique Device Identifier (UDI) systems. These registries help ensure traceability and compliance with global medical device regulations.

The classification of Channel Medsystems’ devices depends on their intended use and associated risks. Their products fall under Class I (generally low-risk devices) and Class III (high-risk devices requiring stringent premarket approval). For example, cryosurgical systems like the Cerene Cryotherapy Device, which involve precise tissue ablation, are typically classified as Class III due to their critical role in patient safety and procedural outcomes.

Yes, Channel Medsystems’ devices are designed for use in both the EU and the US, which is reflected in their regulatory listings. In the EU, they appear in eudamed, ensuring compliance with EU Medical Device Regulations (MDR) or In Vitro Diagnostic Regulation (IVDR). In the US, their devices are tracked in the FDA’s PMA (for high-risk Class III devices) and UDI systems, which require unique identifiers for traceability and post-market surveillance. This dual listing ensures alignment with both regional regulatory requirements.